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Abstract
Transcatheter aortic valve implantation (TAVI) has become an established therapeutic option for patients with
symptomatic, severe aortic valve stenosis. Ageing of the Western and Asian population and expansion of
indications for TAVI will lead to a substantial increase in the number of TAVI procedures performed worldwide
within the next decades. In line with the maturation of TAVI over the past few years, there has also been a
significant simplification and optimisation of the TAVI procedure. A minimalist TAVI procedure and fast-track TAVI
course have been shown to have distinct advantages over the more traditional TAVI approach. The aim of this
manuscript is to discuss strategies of TAVI simplification and optimization, with special focus on fast-track TAVI,
without compromising safety and efficacy.
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Background
In 2002, Cribier et al. reported the first-in-human
transcatheter aortic valve implantation (TAVI), which
marked the beginning of a new era in the treatment of
severe aortic valve stenosis (AS) [1]. In the early days,
TAVI was performed in patients who were surgically
inoperable or at high surgical risk [2, 3]. Pre-procedural
assessment of the aortic valve was mainly done by echo-
cardiography and TAVI was performed under general
anaesthesia with transesophageal echocardiography
(TEE) guidance. As the initial delivery systems were
large, vascular complications were not uncommon. All
these aspects – in combination with a limited operator
experience – often led to complex and prolonged TAVI
procedures and hospital stays.
During the last few years, procedural planning, TAVI
systems, and clinical experience have dramatically im-
proved. Evidence demonstrating the safety and efficacy
of TAVI in patients at intermediate surgical risk has now
become available, and trials are ongoing in patients at
low surgical risk [4, 5]. This expansion of TAVI indica-
tions as well as ageing of the Western and Asian popula-
tions will lead to a substantial increase in the number of
TAVI procedures performed worldwide within the next
decades. Hence, there will be an increasing need for a
simplified and fast-track TAVI approach without
compromising safety and efficacy in order to treat these
larger patient-flows at a reasonable economical cost.
The aim of this manuscript is to discuss strategies of
TAVI simplification and optimization without comprom-
ising safety and efficacy – with special focus on fast-track
TAVI – based on scientific data and our daily clinical
experience in the Copenhagen TAVI center.
Pre-procedural planning
A prerequisite for establishing and running a successful
TAVI program is a thorough pre-procedural planning.
Although cardiac imaging has a central role in the
pre-procedural work-up, other aspects are also important
in order to obtain an optimal clinical pathway.
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Patient selection
Large randomized clinical trials conducted within the
past few years have demonstrated equivalence and even
net superiority of TAVI over surgical aortic valve re-
placement (SAVR) in high and intermediate risk patients
[2–5].The prospect of bringing TAVI to lower risk and
younger patient populations has led interventional cardi-
ologists and cardiothoracic surgeons to dispute how far
to push the limits; trials are ongoing to address this
question.
Recently updated 2017 ESC/EACTS (European Society
of Cardiology/European Association of Cardiothoracic
Surgery) guidelines on the management of valvular heart
disease recommend that the choice for TAVI or SAVR
should not simply be based on age or a surgical risk
score (STS score or EuroSCORE). A multidisciplinary
Heart Team must weigh the risks and benefits of both
procedures and the discussion should include multiple
parameters such as age, functional status, co-morbid
conditions, frailty and social support, in addition to the
patient’s anatomy and the center’s outcomes for TAVI
and SAVR [6]. An overview of the different clinical as
well as anatomical/technical aspects to be considered
are listed in Fig. 1.
Pre-procedural imaging
Pre-procedural imaging and assessment has dramatically
improved as compared to the early days. Nowadays, the
‘gold standard’ is multi detector computed tomography
(MDCT); not only to assess the aortic valve and its
surrounding structures, but also to judge the possible
vascular access routes.
In order to use MDCT as the ‘gold standard’, the
acquisition and MDCT-quality has to apply to certain
standards. The cardiac MDCT should be ECG-gated,
contrast-enhanced and with 0.5 mm slice-thickness; the
vascular access MDCT is best contrast-enhanced and
with 1.0 mm slice-thickness. Based on a meticulous
MDCT assessment, important considerations can be
made: (1) anatomical findings that could favour SAVR or
TAVI (see Fig. 1); (2) the TAVI access routes can be
assessed with a preference for the transfemoral (TF)
route; (3) in case different types of transcatheter heart
valves (THV) are available at a center, a THV choice tai-
lored to the patient’s anatomy can be made which may
theoretically result in better outcomes. In case of alter-
native, non-TF access, the anatomical and technical as-
pects of the different access routes (subclavian, axillary,
transcarotid, direct aortic, transcaval, transapical) should
be discussed with the cardiothoracic surgeon.
Concomitant disease
When discussing a patient with symptomatic, severe AS,
it is important to obtain a ‘full picture’ of the patient
needing treatment. As indicated in Fig. 1, concomitant
diseases or conditions may have an impact on the deci-
sion for TAVI vs. SAVR. In addition, some aspects may
have an impact on the decision to plan the TAVI proced-
ure in general anaesthesia (GA) vs. local anaesthesia
(LA); e.g. severe lung disease or pulmonary hyperten-
sion, Parkinson’s disease with complex poly-pharmacy,
conditions that may affect the rehabilitation process, etc.
Assessment of the coronary arteries before TAVI is
also a standard practice. The ESC/EACTS guidelines
recommend percutaneous coronary intervention (PCI)
in patients undergoing TAVI with greater than 70% sten-
osis at proximal coronary segments [7].However, there is
currently no conclusive evidence as to whether PCI
should be performed or not, and whether a staged or
hybrid intervention should be preferred. The decision
should be made on an individual basis depending on the
leading clinical problem, the complexity of the under-
lying coronary artery disease, and the presence of
co-morbidities such as renal dysfunction [8].
Patient information
Finally, it is important that the decision taken by the
Heart Team with regards to the type of therapy, anaes-
thesia, and route of access in case of TAVI is communi-
cated to the patient and the relatives. Patients should be
counselled about the risks/benefits of the procedure and
the different steps to come. A thorough pre-procedural
work-up and good patient information helps to prepare
the patient for early mobilisation and early discharge
(if possible).
Centres with a high volume TAVI program frequently
have Transcatheter Valve Therapies (TVT) or TAVI co-
ordinators. This function plays an important role in: (1)
streamlining and prioritizing referrals for TAVI; (2) clin-
ical assessment of the patient by means of mini-mental
state examination, 6-min walk test, frailty test, etc.; (3)
making appointments for MDCT and transthoracic
echocardiography (TTE); and (4) coordinating care for
the out- and in-patient settings. This may reduce the
preparatory time required by physicians and free them
for other more physician-specific tasks [9].
Minimalist TAVI
In line with the maturation of TAVI over the past
decade, there has also been a significant simplification
of the TAVI procedure. A simplified or minimalist
TAVI approach (Fig. 2a and b) has been shown to be
as safe and effective as the more traditional approach
and is nowadays routine in many centers [10–14].
Minimalist TAVI not only leads to a reduced proced-
ural time but also a shorter intensive care unit (ICU)
and hospital stay, lower resource use and lower
hospital costs [10, 12, 14, 15].
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Transfemoral approach
Maximization of TF access is one of the most import-
ant aspects when trying to maximally exploit the
benefits of a minimalist TAVI approach (Fig. 2b).
Nowadays, most of the TAVI procedures– even those
with challenging peripheral access – can be per-
formed by TF approach using low profile sheaths and
devices [16]. In a meta-analysis by Zhao et al.,
TF-TAVI was reported to result in a higher 30-day
and 1-year survival as compared to transapical TAVI
[17]. In a meta-analysis by Siontis et al., a lower
2-year mortality rate was reported for TF-TAVI as
compared to SAVR, whereas this was not true for
alternative access TAVI [18]. However, interpretation
of these results is difficult as transapical and alterna-
tive access TAVI groups also typically contain a larger
number of patients at higher surgical risk with
multiple co-morbidities.
In order to fully exploit all benefits of the TF
approach, a true percutaneous approach with the use of
a vascular (pre)-closure device should be adopted [19].
Routine use of ultrasound-guided vascular puncture
and a safety wire help to keep major vascular compli-
cations to a minimum. In case of incomplete vascular
closure or vascular closure device failure, percutan-
eous intervention using balloon tamponade and/or a
covered stent should be part of the operator’s team
therapeutic arsenal [20].
Local anaesthesia
As the majority of TAVI nowadays are performed by TF
approach, this has also led to an increased adoption of
LA or conscious sedation. GA in many centers is used
only in case of alternative access. However, even though
most operators are convinced that TF-TAVI is optimal
when possible, some still favor GA over LA [21].
Fig. 1 Pre-procedural planning. Clinical and anatomical/technical aspects to be considered for the decision TAVI (+) vs. SAVR (−) in the Heart
Team meeting – based on the 2017 ESC/EACTS guidelines for the treatment of valvular heart disease. CABG, coronary artery bypass grafting;
EACTS, European Association of Cardio-Thoracic Surgery; Euroscore II, European System for Cardiac Operative Risk Evaluation; SAVR, surgical aortic
valve replacement; STS, Society of Thoracic Surgery; TAVI, transcatheter aortic valve implantation
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Depending on local routines, politics and/or legisla-
tion, TAVI procedures are performed with or without
anaesthesia support in the cathlab. Also specific patient
characteristics (e.g. extreme obesity, mental disorder,
chronic backpain) may still favor the use of GA for cer-
tain TAVI procedures at our center (Fig. 2a). One of the
largest advantages of performing TAVI without GA is
that patients tend to be hemodynamically more stable
with less need for inotropic agents. TAVI with LA only
is also the better choice for patients with significant lung
disease or pulmonary hypertension. Moreover, perform-
ing TAVI under LA has a distinct advantage as monitor-
ing of the neurological status is possible thoughout the
entire procedure; it also allows pain assessment which is
important during certain phases of the procedure as pain
can signal risk for vascular complication [22]. Several
studies report that TAVI under LA is at least as safe as
TAVI under GA [23–25]. Furthermore, there is a
reduced procedural time, no longer need for ICU stay,
and a reduced length of hospital stay; all these aspects
make TAVI under LA a cost-effective alternative to
TAVI under GA [23–25].
Paravalvular leak (PVL) assessment
As TAVI is increasingly performed in LA or conscious
sedation only, use of peri-procedural TEE to assess PVL
is no longer routine in many centers. The use of TEE
demands GA and data supports the fact that clinical
outcomes are similar for TAVI under LA without TEE
vs. TAVI under GA with TEE, with LA offering other
advantages as explained above [13, 14, 23–27]. In one
study, TAVI with TTE only in a high-risk patient group
was associated with an increased incidence of
intra-procedural PVL, although this was not associated
with higher rates of PVL at follow-up [28]. However, it
is important not to rely on one measurement only – in
Fig. 2 Minimalist TAVI. a Criteria to be considered when deciding on minimalist TAVI or not. b Different aspects to be considered in order to
simplify the TAVI procedure. ECG, electrocardiogram; IV, intravenous; LA, local anesthesia; PM, pacemaker; PVL, paravalvular leak; TAVI,
transcatheter aortic valve implantation; TF, transfemoral; THV, transcatheter heart valve; TTE, transthoracic echocardiography
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order to assess the grade of PVL immediately after THV
implantation, most operators take a combined evaluation
of aortography, hemodynamic parameters and TTE.
Minimum of catheters and lines
A policy of ‘no catheters except for one peripheral
venous line’ adds to the simplification of TAVI. A recent
observational TAVI study suggests that avoidance of
bladder catheterization minimizes in-hospital complica-
tions, with significantly lower rates of urinary infection,
haematuria and need for continuous bladder irrigation
[29]. Also a central venous line has its own complica-
tions and is best avoided, if possible [30].
Newer THV devices
Availability and use of newer THV devices may help
when implementing minimalist TAVI, as these newer
devices have a lower insertion profile, are often reposi-
tionable, have a more stable and predictable valve
deployment, and have a lower incidence of significant
PVL. It is a debated topic from which annual TAVI
volume a second THV system should be introduced in a
center. A difficult balance should be kept between
increased experience with a specific THV vs. the oppor-
tunity to choose a specific THV type tailored to the
patient’s specific anatomy. Clearly, it is an advantage if
TAVI cases can be centralized in a larger volume TAVI
center as this will not only result in a higher quality
TAVI program, but this will also give the possibility to
have different THV devices in use.
Pacemaker
Routine use of a balloon-tipped temporary pacemaker
(PM) may reduce the risk of right ventricular perfor-
ation. Another possibility is to pace the left ventricle
(LV) by using the stiff guidewire in the LV, which may
further add to TAVI simplification [31]. In our center,
the temporary PM is removed in the cathlab in the ma-
jority of cases after assessment of a post-TAVI ECG and
with the help of a pre-specified protocol [32]. One other
study also showed that patients with normal PR and
QRS conduction post-TAVI did not develop delayed
high-degree conduction disorders [33]. These patients
are the best candidates for removal of their temporary
PM in cathlab. In case of high-degree conduction disor-
ders, switching the temporary PM from a transfemoral
to a transjugular insertion with a screw-in lead helps to
mobilize these patients early after the TAVI procedure.
TAVI team
When having the ambition to be a center of excellence,
it is must to build a dedicated TAVI team involving
experienced TAVI operators, cathlab nurses who are also
trained in valve loading, and a TAVI coordinator. As for
most interventions, a large experience is often the best
guarantee for a high success rate. Also for the imple-
mentation of minimalist TAVI, it is an advantage to be
able to rely on a team with large expertise in TAVI and
basic peripheral vascular intervention skills. A dedicated
hybrid lab is the preferred work place.
Post-procedural care
Early mobilization
As the majority of TAVI cases nowadays can be per-
formed by a true percutaneous TF approach without the
need for GA, most of these patients can immediately
after completion of the procedure be transferred from
the catheterization laboratory to the telemetry floor
(Fig. 3). This not only eliminates a large ‘burden’ on the
ICU, but also results in a significant cost reduction. Only
those patients that underwent alternative access TAVI or
those with peri-procedural complications are still moni-
tored at ICU during the post-procedural period.
Early mobilisation from 6 h after TAVI and discharge
within 24 to 48 h should be aimed for as not only does it
result in cost savings, but can also reduce the risk of
post-operative delirium and result in a faster improve-
ment of the patient’s quality of life [34, 35].
Decision on permanent pacemaker
An internal protocol for the evaluation of conduction
disorders and, hence, decision on the need for a perman-
ent PM within 24 h after TAVI helps to reduce the hos-
pital length of stay (LoS). In case a permanent PM is
needed, implantation within 72 h after TAVI should be
aimed for as this helps avoiding unnecessary prolonga-
tion of the hospitalization.
Length of hospitalization
In 2016, the Vancouver group reported on their TAVI
clinical pathway, thereby implementing a minimalist
TAVI approach, standardized care, and discharge criteria
to reduce LoS. Between May 2012 and October 2014,
397 TF-TAVI were completed – of these, 150 (38.2%)
were discharged within 48 h, whereas only 39 patients
(9.9%) were hospitalized for more than 5 days [36]. In
our experience in Copenhagen, 543 patients underwent
TF-TAVI in the 2016–2017 period – of these 314
(57.8%) were discharged within 48 h, whereas 43 patients
(7.9%) were hospitalized for more than 5 days (Fig. 4).
Clearly, LoS after TAVI is not only depending on the
optimization and implementation of clinical pathways,
but also on the risk profile of the TAVI population and
rules for reimbursement in specific countries. Import-
antly, a short post-procedural LoS was not associated
with an increased risk of readmission within 30 days or
1 year. On the contrary, the risk of 1-year readmission
increased with longer post-TAVI LoS [37]. Few other
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studies also suggest no difference in 30-day rehospitali-
sation and clinical outcomes in case of early discharge
after TF-TAVI [38, 39].
Anti-thrombotic regimen
Currently, there is still a lot of debate and uncertainty
about the optimal post-procedural anti-thrombotic treat-
ment following TAVI. Numerous on-going trials are
comparing different anti-platelet and anti-thrombotic
regimens in patients undergoing TAVI. Only small
studies in TAVI patients are available, which are mostly
observational and likely underpowered.
The current AHA/ACC (American Heart Associ-
ation/American College of Cardiology) guidelines and
ESC/EACTS guidelines recommend dual antiplatelet
therapy (DAPT) for 3 to 6 months followed by aspirin
lifelong. However, it is generally expected that these
recommendations will be further ‘simplified’ in the
near future. Preliminary data seem to indicate that
single antiplatelet therapy may be as safe and as ef-
fective as DAPT for patients undergoing TAVI. ESC/
EACTS guidelines suggest that single antiplatelet
therapy may be considered instead of DAPT in
patients with high bleeding risk [6, 40, 41].
Oral anticoagulation is treatment of choice in patients
who have other indications for anticoagulation like
Atrial fibrillation (AF), venous thromboembolism, hyper-
coagulable state or, with a lesser degree of evidence, se-
verely impaired LV dysfunction (ejection fraction < 35%)
[6]. Anticoagulation with a Vitamin K antagonists (VKA)
to achieve an INR of 2.5 may be reasonable for at least
3 months after TAVR in patients at low risk of bleeding
[40]. In patients with AF, VKA will remain the treatment
of choice. However, additional antiplatelet therapy seems
Fig. 3 Post-procedural management. a Different aspects to be considered in order to optimize post-TAVI care and obtain a ‘fast-track’ TAVI
course. b Check-list for possible early discharge within 24 to 48 h after TAVI – as applied at the Copenhagen TAVI center. CRP, C reactive protein;
ECG, electrocardiogram; ICU, intensive care unit; NYHA, New York Heart Association; PM, pacemaker; RBBB, right bundle branch block; TAVI,
transcatheter aortic valve implantation; THV, transcatheter heart valve; TIA, Transient ischemic attack; TTE, transthoracic echocardiography
Chopra et al. BMC Cardiovascular Disorders          (2018) 18:231 Page 6 of 9
only reasonable in patients with recent acute coronary
syndrome, extensive or recent coronary stenting or large
aortic arch atheroma. Initiation of VKA is indicated in
clinical valve leaflet thrombosis, whereas the role of
VKA in the case of subclinical leaflet thrombosis is
currently uncertain [42].
Follow-up
As more than 75% of TF-TAVI patients are discharged
within 72 h in Copenhagen, we routinely foresee a
follow-up consultation with the general practitioner
approximately one week after TAVI for all patients. In
this way, patients are guaranteed a clinic visit, checking
for fever (in case of infection), dizziness (in case of
conduction disorders), or taking blood samples in case
of reduced renal function or borderline elevated infec-
tion parameters at discharge. Routine ‘home-care’ in frail
elderly patients, follow-up at a local heart failure clinic
in patients with reduced LV function, and referral of all
patients to a cardiac rehabilitation program adds to
comprehensive patient management. In this context, an
Italian study previously reported that involving TAVI pa-
tients in a cardiac rehabilitation program significantly
improves their functional status, quality of life, and
autonomy [43].
Concerning echocardiographic follow-up post-TAVI,
the most recent European guidelines prescribe a TTE
before discharge followed by echocardiographic assess-
ment of the valve function at 1 to 3 months after TAVI,
at 1 year after TAVI and annually thereafter (with
additional follow-up assessment and/or integration of
other imaging modalities as necessary and/or deter-
mined by the attending physician) in order to diagnose
possible valve failure or valve dysfunction in time [44].
Conclusion
Expansion of indications for TAVI and ageing of the
Western/Asian population will lead to a substantial
Fig. 4 Copenhagen TAVI experience. Results from the East Denmark Heart Registry reporting on the TAVI approach and short-term clinical
outcomes in the period 2008 to 2017. GA, general anaesthesia; LA, local anaesthesia; PM, pacemaker; TAVI, transcatheter aortic valve implantation;
TF, transfemoral
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increase in the number of TAVI procedures performed
worldwide within the next decades. A minimalist TAVI
procedure and fast-track TAVI course have been shown
to have distinct advantages over the more traditional
approach without compromising safety and clinical
efficacy. Moreover, this TAVI optimization creates the
opportunity to reduce the burden on hospital resources
and add to cost-effectiveness when confronted with a
growing population of patients with severe AS.
Abbreviations
ACC: American College of Cardiology; AF: Atrial fibrillation; AHA: American
Heart Association; AS: Aortic valve stenosis; CABG: Coronary artery bypass
grafting; CRP: C reactive protein; DAPT: Dual antiplatelet therapy;
EACTS: European Association of Cardio-Thoracic Surgery; ECG: 12- lead
Electrocardiogram; ESC: European Society of Cardiology;
EuroSCORE: European System for Cardiac Operative Risk Evaluation;
GA: General anaesthesia; ICU: Intensive care unit; IV: Intravenous; LA: Local
anaesthesia; LoS: Hospital length of stay; LV: Left ventricle; MDCT: Multi
detector computed tomography; NYHA: New York Heart Association;
PCI: Percutaneous coronary intervention; PM: Pacemaker; PVL: Paravalvular
leak; RBBB: Right bundle branch block; SAVR: Surgical aortic valve
replacement; STS: Society of Thoracic Surgery; TAVI: Transcatheter aortic valve
implantation; TEE: Transesophageal echocardiography; TF: Transfemoral;
THV: Transcatheter heart valves; TIA: Transient ischemic attack;
TTE: Transthoracic echocardiography; TVT: Transcatheter valve therapies;
VKA: Vitamin K antagonist
Acknowledgements
None.
Funding
None.
Availability of data and materials
Not applicable.
Authors’ contributions
Equal. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Received: 3 October 2018 Accepted: 3 December 2018
References
1. Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, et al.
Percutaneous transcatheter implantation of an aortic valve prosthesis for
calcific aortic stenosis: first human case description. Circulation.
2002;106(24):3006–8.
2. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al.
Transcatheter aortic-valve implantation for aortic stenosis in patients who
cannot undergo surgery. N Engl J Med. 2010;363(17):1597–607.
3. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al.
Transcatheter versus surgical aortic-valve replacement in high-risk patients.
N Engl J Med. 2011;364(23):2187–98.
4. Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, et al.
Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk
Patients. N Engl J Med. 2016;374(17):1609–20.
5. Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Søndergaard L,
Mumtaz M, et al. Surgical or Transcatheter aortic-valve replacement in
intermediate-risk patients. N Engl J Med. 2017;376(14):1321–31.
6. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. 2017
ESC/EACTS Guidelines for the management of valvular heart disease.
Eur Heart J. 2017;38(36):2739–91.
7. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. 2014
ESC/EACTS guidelines on myocardial revascularization: the task force on
myocardial revascularization of the European Society of Cardiology (ESC)
and the European Association for Cardio-Thoracic Surgery
(EACTS)developed with the special contribution of the European
Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart
J. 2014;35(37):2541–619.
8. Goel SS, Ige M, Tuzcu EM, Ellis SG, Stewart WJ, Svensson LG, et al. Severe
aortic stenosis and coronary artery disease: implications for management in
the transcatheter aortic valve replacement era: a comprehensive review.
J Am Coll Cardiol. 2013;62(1):1–10.
9. Coylewright M, Mack MJ, Holmes DR Jr, O'Gara PT. A call for an evidence-
based approach to the heart team for patients with severe aortic stenosis.
J Am Coll Cardiol. 2015;65(14):1472–80.
10. Babaliaros V, Devireddy C, Lerakis S, Leonardi R, Iturra SA, Mavromatis K,
et al. Comparison of Transfemoral transcatheter aortic valve replacement
performed in the catheterisation laboratory (minimalistic approach) versus
hybrid operating room (Standard approach): outcomes and cost analysis.
JACC Cardiovasc Interv. 2014 Aug;7(8):898–904.
11. Frangieh AH, Ott I, Michel J, Shivaraju A, Joner M, Mayr NP, et al.
Standardized minimalistic Transfemoral Transcatheter aortic valve
replacement (TAVR) using the SAPIEN 3 device: stepwise description,
feasibility, and safety from a large consecutive single-center single-operator
cohort. Structural Heart. 2017;1(3–4):169–78.
12. Gurevich S, Oestreich B, Kelly RF, Mbai M, Bertog S, Ringsred K, et al.
Outcomes of transcatheter aortic valve replacement using a minimalist
approach. Cardiovasc Revasc Med. 2018;19(2):192–5.
13. Barbanti M, Tamburino C. Optimisation of TAVI: is it mature enough to be
defined as a PCI-like procedure? EuroIntervention. 2015;11 Suppl W:W110–3.
14. Jensen HA, Condado JF, Devireddy C, Binongo J, Leshnower BG, Babaliaros
V, et al. Minimalist transcatheter aortic valve replacement: the new standard
for surgeons and cardiologists using transfemoral access? J Thorac
Cardiovasc Surg. 2015;150(4):833–9.
15. Ribera A, Slof J, Andrea R, Falces C, Gutiérrez E, Del Valle-Fernández R, et al.
Transfemoral transcatheter aortic valve replacement compared with surgical
replacement in patients with severe aortic stenosis and comparable risk:
cost-utility and its determinants. Int J Cardiol. 2015;182:321–8.
16. Barbanti M, Binder RK, Freeman M, Wood DA, Leipsic J, Cheung A, et al.
Impact of low-profile sheaths on vascular complications during transfemoral
transcatheter aortic valve replacement. EuroIntervention. 2013;9(8):929–35.
17. Zhao A, Minhui H, Li X, Zhiyun X. A meta-analysis of transfemoral versus
transapical transcatheter aortic valve implantation on 30-day and 1-year
outcomes. Heart Surg Forum. 2015;18(4):E161–6.
18. Siontis GC, Praz F, Pilgrim T, Mavridis D, Verma S, Salanti G, et al.
Transcatheter aortic valve implantation vs. surgical aortic valve replacement
for treatment of severe aortic stenosis: a meta-analysis of randomized trials.
Eur Heart J. 2016;37(47):3503–12.
19. Israel M, Barbash IM, Barbanti M, Webb J, Molina-Martin De Nicolas J,
Abramowitz Y, et al. Comparison of vascular closure devices for access site
closure after transfemoral aortic valve implantation. Eur Heart J.
2015;36(47):3370–9.
20. Stortecky S, Wenaweser P, Diehm N, Pilgrim T, Huber C, Rosskopf AB, et al.
Percutaneous management of vascular complications in patients
undergoing transcatheter aortic valve implantation. JACC Cardiovasc Interv.
2012 May;5(5):515–24.
21. Marcantuono R, Gutsche J, Burke-Julien M, Anwaruddin S, Augoustides JG,
Jones D, et al. Rationale, development, implementation, and initial results of
a fast track protocol for transfemoral transcatheter aortic valve replacement
(TAVR). Catheter Cardiovasc Interv. 2015;85(4):648–54.
22. Dvir D, Jhaveri R, Pichard AD. The minimalist approach for transcatheter
aortic valve replacement in high-risk patients. JACC Cardiovasc Interv.
2012;5(5):468–9.
Chopra et al. BMC Cardiovascular Disorders          (2018) 18:231 Page 8 of 9
23. Jabbar A, Khaurana A, Mohammed A, Das R, Zaman A, Edwards R. Local
versus general Anaesthesia in Transcatheter aortic valve replacement.
Am J Cardiol. 2016;118(11):1712–6.
24. Villablanca PA, Mohananey D, Nikolic K, Bangalore S, Slovut DP, Mathew V,
et al. Comparision of local versus general anaesthesia in patients
undergoing transcatheter aortic valve replacement: A meta-analysis.
Catheter Cardiovasc Interv. 2018;91(2):330–42.
25. Fröhlich GM, Lansky AJ, Webb J, Roffi M, Toggweiler S, Reinthaler M, et al.
Local versus general anaesthesia for transcatheter aortic valve implantation
(TAVR) – Systematic review and meta-analysis. BMC Med. 2014;12:41.
26. Krishnaswamy A, Latib A, Malik A, Bertoldi L, Poddar KL, Chieffo A, et al.
Resource utilization for transfemoral transcatheter aortic valve replacement:
an international comparision. Catheter Cardiovasc Interv. 2016;87(1):145–51.
27. Cilingiroglu M, Marmagkiolis K. A glimpse into future of TAVR. Catheter
Cardiovasc Interv. 2016;87(1):152–3.
28. Hayek SS, Corrigan FE 3rd, Condado JF, Lin S, Howell S, MacNamara JP, et al.
Paravalvular Regurgitation after Transcatheter Aortic Valve Replacement:
Comparing Transthoracic versus Transesophageal Echocardiographic
Guidance. J Am Soc Echocardiogr. 2017;30(6):533–40.
29. Lauck SB, Kwon JY, Wood DA, Baumbusch J, Norekvål TM, Htun N, et al.
Avoidance of urinary catheterization to minimize in-hospital complications
after transcatheter aortic valve implantation: an observational study.
Eur J Cardiovasc Nurs. 2018;17(1):66–74.
30. Kornbau C, Lee KC, Hughes GD, Firstenberg MS. Central line complications.
Int J Crit Illn Inj Sci. 2015;5(3):170–8.
31. Faurie B, Abdellaoui M, Wautot F, Staat P, Champagnac D, Wintzer-
Wehekind J, et al. Rapid pacing using the left ventricular guidewire:
Reviving an old technique to simplify BAV and TAVI procedures. Catheter
Cardiovasc Interv. 2016;88(6):988–93.
32. Jørgensen TH, De Backer O, Gerds TA, Bieliauskas G, Svendsen JH,
Søndergaard L. Immediate post-procedural 12-Lead electrocardiography as
predictor of late conduction defects after Transcatheter aortic valve
replacement. JACC Cardiovasc Interv. 2018;11(15):1509–18.
33. Toggweiler S, Stortecky S, Holy E, Zuk K, Cuculi F, Nietlispach F, et al. The
electrocardiogram after Transcatheter aortic valve replacement determines
the risk for post-procedural high-degree AV block and the need for
telemetry monitoring. JACC Cardiovasc Interv. 2016;9(12):1269–76.
34. Wood DA. Could a Simplified Transcatheter Aortic Valve Replacement
Procedure Eliminate Post –Operative Delirium? JACC Cardiovasc Interv.
2016;9(2):169–70.
35. Abawi M, Nijhoff F, Agostoni P, Emmelot-Vonk MH, de Vries R, Doevendans
PA, et al. Incidence, predictive factors, and effect of delirium after
transcatheter aortic valve replacement. JACC Cardiovasc Interv.
2016;9(2):160–8.
36. Lauck SB, Wood DA, Baumbusch J, Kwon JY, Stub D, Achtem L, et al.
Vancouver transcatheter aortic valve replacement clinical pathway:
minimalist approach, standardized care, and discharge criteria to reduce
length of stay. Circ Cardiovasc Qual Outcomes. 2016;9(3):312–21.
37. Sud M, Qui F, Austin PC, Ko DT, Wood D, Czarnecki A, et al. Short Length of
Stay After Elective Transfemoral Transcatheter Aortic Valve Replacement is
Not Associated With Increased Early or Late Readmission Risk. J Am Heart
Assoc. 2017;6(4):e005460.
38. Durand E, Eltchaninoff H, Canville A, Bouhzam N, Godin M, Tron C, et al.
Feasibility and safety of early discharge after transfemoral transcatheter
aortic valve implantation with the Edwards SAPIEN-XT prosthesis.
Am J Cardiol. 2015;115(8):1116–22.
39. Barbanti M, Capranzano P, Ohno Y, Attizzani GF, Gulino S, Imme S, et al.
Early discharge after transfemoral transcatheter aortic valve implantation.
Heart. 2015;101(18):1485–90.
40. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA,
et al. 2017 AHA/ACC focused update of the Management of Patients with
Valvular Heart Disease: a report of the American College of Cardiology/
American Heart Association task force on clinical practice guidelines.
J Am Coll Cardiol. 2017;70(2):252–89.
41. Ahmad Y, Demir O, Rajkumar C, Howard JP, Shun-Shin M, Cook C, et al.
Optimal antiplatelet strategy after transcatheter aortic valve implantation: a
meta-analysis. Open Heart. 2018;5(1):e000748.
42. Søndergaard L, Sigitas C, Chopra M, Bieliauskas G, De Backer O. Leaflet
Thrombosis after TAVI. Eur Heart J. 2017;38(36):2702–3.
43. Zanettini R, Gatto G, Mori I, Pozzoni MB, Pelenghi S, Martinelli L, et al.
Cardiac rehabilitation and mid-term follow-up after transcatheter aortic
valve implantation. J Geriatr Cardiol. 2014;11(4):279–85.
44. Capodanno D, Petronio AS, Prendergast B, Eltchaninoff H, Vahanian A,
Modine T, et al. Standardized definations of structural deterioration and
valve failure in assessing long-term durability of transcatheter and surgical
aortic bioprostheic valves: a consensus statement from the European
Association of Percutaneus Cardiovascular Interventions (EAPCI) endorsed
by the European Society of Cardiology (ESC) and the European Association
for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2017;38(45):3382–90.
Chopra et al. BMC Cardiovascular Disorders          (2018) 18:231 Page 9 of 9
